PMC8652916_01
Pulmonary tumor squamous cell histology analysis. (A) P40 immuno- histochemistry stain, 20x; (B) P63 immunohistochemistry stain, 20x magnification demonstrating squamous differentiation.
OTT-14-5385-g0001.jpg
PMC8652916_01_OTT-14-5385-g0001.jpg
f0001
Immunohistochemistry (IHC) revealed that CK7, CK5/6, P63, and P40 were positive (Figure 1), whereas TTF-1 and NapsinA were negative.
Brain MRI with contrast demonstrating one brain metastatic lesion (red arrows), (A) is at diagnosis, (B) following 6 months of alectinib treatment, and (C) following 9 months of alectinib.
OTT-14-5385-g0002.jpg
PMC8652916_01_OTT-14-5385-g0002.jpg
f0002
In March 2021, imaging evaluation revealed CR in the intracranial metastases and both lung lesions (Figures 2 and 3); however, the mediastinal and cervical lymph nodes were larger than before, and new metastases appeared in the first lumbar vertebra.
Chest computed tomography scans demonstrating numerous metastatic (red arrows), (A-C) at diagnosis, (D-F) following 3 months of alectinib treatment, and (G-I) following 9 months of alectinib.
OTT-14-5385-g0003.jpg
PMC8652916_01_OTT-14-5385-g0003.jpg
f0003
In March 2021, imaging evaluation revealed CR in the intracranial metastases and both lung lesions (Figures 2 and 3); however, the mediastinal and cervical lymph nodes were larger than before, and new metastases appeared in the first lumbar vertebra.